Following adults with asthma, COPD, bronchiectasis, cystic fibrosis or ciliary dyskinesia
Observes people with long-term inflammatory lung diseases to compare their features.
Key facts
- Who runs it
- CHU de Reims
- Where
- Reims, FranceSee the site
- Trial code
- Registry title
- A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
- Status
- Recruiting
- People taking part
- 470 people, planned
- Started
- 15 Sept 2025
- Expected to end
- 15 Sept 2040
- Type of study
- Observational
- Treatments tested
- Non applicable
- Record updated
- 20 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults followed for asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia or interstitial lung disease. Healthy volunteers can join as controls.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Follow-up for asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia or interstitial lung disease.
Main reasons for not taking part
- People protected by law, for example with legal incapacity
- Any condition that prevents informed consent or taking part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age ≥ 18 years
- Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD)
- Healthy volunteers (controls)
Who cannot take part
- Any condition preventing informed consent or participation
- Subjects protected by law (e.g., legal incapacity)
Where in France
- CHU ReimsReims, FranceContact: Damien JOLLYTaking people
About the trial
What the trial wants to find out
Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are characterised by lung inflammation and remodelling. Clinical, functional, microbiological, biological, pathological and prognostic features are highly variable and heterogeneous. Several phenotypes have been described within the same pathology, as similar phenotypic traits between different pathologies, or the coexistence of components of several diagnoses in the same patient, suggesting shared underlying mechanisms that could represent new therapeutic targets, beyond the initial medical diagnosis.
Read full original descriptionShow less
The objectives of this prospective study are to analyze the phenotypic characteristics (clinical, demographic, biological, morphological, pathological, and microbiological characteristics) together with respiratory exposures and underlying mechanisms involving airway epithelium and inflammation processes in a cohort of patients diagnosed with asthma, COPD, bronchiectasis, CF, PCD and ILD.
Treatments tested
- Non applicable
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
- Plain-language title
- Following adults with asthma, COPD, bronchiectasis, cystic fibrosis or ciliary dyskinesiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 February 2026